Intellia says CRISPR therapy shows superior gain for cardiomyopathy patients

Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day. Repeatedly, the company has announced positive data from its gene editing trials, only to watch the stock slide.

The stock market is notoriously fickle, particularly around buzzy gene-editing companies. Yet the selloffs pointed to real questions around the biotech’s programs: Clearly, its CRISPR-based drugs were effective. But were they any more effective than other drugs that use older, less sci-fi technologies?

Intellia tried to allay some of those concerns on Saturday with new year-long data from the 36 patients treated in an early trial of its CRISPR drug for ATTR cardiomyopathy.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

AR/VR in Healthcare: Why Collaboration is its Most Important Use

Wyatt Oren, Director of Sales, Telehealth and EdTech, Agora Throughout history, new and emerging technologies have helped revolutionize and advance the field of medicine, allowing

May 1, 2024

Dentists are pulling ‘healthy’ and treatable teeth to profit from implants, experts warn

Becky Carroll was missing a few teeth, and others were stained or crooked. Ashamed, she smiled with lips pressed closed. Her dentist offered to fix

November 1, 2024

Lonza, Vertex to build a new cell therapy manufacturing facility for the biotech’s type 1 diabetes therapies

The Swiss contract manufacturer Lonza and Vertex plan to build a facility designed to manufacture the biotech’s type 1 diabetes cell therapies in a deal

June 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.